925 withdrawn. 925 Phase 1, 348 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 925 | Withdrawn 925 |
| Phase 2 | 348 | Withdrawn 348 |
Follow Neoplasms: new trials by email Literature Review of Neoplasms trials Research Report on Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC certepetide, nab-paclitaxel, gemcitabine - Pancreas Cancer, Pancreatic Carcinoma | Phase 1 / Phase 2 | Withdrawn | Lisata Therapeutics, Inc. | 2030-01-01 | 2025-06-06 | |
| ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2027-06-01 | 2026-09-11 | |
| Antitumor-B KAC PK Study Antitumor B KAC - Squamous Cell Carcinoma of the Oral Cavity | Phase 1 | Withdrawn | Medical College of Wisconsin | 2026-12-01 | 2025-03-18 | |
| Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function Larotinib - Esophageal Cancer, Advanced Solid Tumor | Phase 1 | Withdrawn | Sunshine Lake Pharma Co., Ltd. | 2026-10-30 | 2026-09-28 | |
| Pre-emptive Anakinra for Cytokine Event Reduction Anakinra (Kineret®) - B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy | Phase 1 / Phase 2 | Withdrawn | Kevin McNerney | 2026-10-01 | 2026-08-13 | |
| Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones Biospecimen Collection, Bone Scan, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2026-10-01 | 2026-08-28 | |
| Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma Arm 1 cemiplimab, Arm 2 cemiplimab and fianlimab - Hepatocellular Carcinoma | Phase 1 | Withdrawn | Virginia Commonwealth University | 2026-10-01 | 2026-09-14 | |
| A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Withdrawn | Children's Oncology Group | 2026-09-10 | 2026-05-05 | |
| Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer Nogapendekin Alfa Inbakicept (N803), Sotevtamab, Zabadinostat (CXD101) - Pancreatic Cancer Resectable, Pancreatic Cancer | Phase 1 | Withdrawn | ImmunityBio, Inc. | 2026-09-01 | 2026-08-28 | |
| Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors ERW316, Fulvestrant, Letrozole - Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors | Phase 1 / Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2026-06-30 | 2026-06-22 | |
| Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC AAA602, AAA802, Gallium (68Ga) gozetotide - Prostate Cancer | Phase 1 / Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2026-06-29 | 2025-12-29 | |
| Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy SV-BR-1-GM Vaccine, Cyclophosphamide, Pembrolizumab - Brain Metastases, Leptomeningeal Metastasis | Phase 1 | Withdrawn | Medical College of Wisconsin | 2026-06-15 | 2026-06-17 | |
| ENLIGHT-AML - An Open-label, Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia GB3226 - Relapsed/Refractory Acute Myeloid Leukemia (AML) | Phase 1 | Withdrawn | Galecto Biotech AB | 2026-06-10 | 2026-07-06 | |
| Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma Activated T cells - Recurrent Glioblastoma | Phase 1 | Withdrawn | Jeremy Rudnick, M.D | 2026-06-01 | 2025-10-22 | |
| A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer Fluzone Quadrivalent - Breast Cancer, Breast Cancer Triple Negative | Phase 1 | Withdrawn | Rush University Medical Center | 2026-06-01 | 2026-03-11 | |
| CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors Dose Level -1, Dose Level 1 (starting dose level), Dose Level 2 - Lymphoma, Myeloma | Phase 1 | Withdrawn | Baylor College of Medicine | 2026-06-01 | 2026-09-16 | |
| Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma Biopsy, Biospecimen Collection, Computed Tomography - Soft Tissue Sarcoma | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2026-05-15 | 2025-08-26 | |
| Retreatment With CTL019/CTL119 CD19 redirected autologous T cells (CTL019 or CTL119 cells) - Lymphoma, B-Cell | Phase 1 | Withdrawn | University of Pennsylvania | 2026-05-01 | 2026-07-22 | |
| A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia Fludarabine, Cytarabine, G-CSF - Phase I, FLAG Chemotherapy | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2026-04-27 | 2026-05-07 | |
| Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer Tarlatamab, Sacituzumab Govitecan - Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2026-04-25 | 2026-04-28 |
Showing 20 of 925. Sign in to see all of them.
Breast Neoplasms (87) · Carcinoma, Non-Small-Cell Lung (71) · Leukemia, Myeloid, Acute (70) · Lymphoma (57) · Pancreatic Neoplasms (51) · Leukemia (47) · Melanoma (47) · Multiple Myeloma (44) · Leukemia, Lymphocytic, Chronic, B-Cell (43) · Lung Neoplasms (42) · Neoplasm Metastasis (42) · Ovarian Neoplasms (42) · Recurrence (42) · Lymphoma, Non-Hodgkin (41)
Neoplasms by Histologic Type (550) · Neoplasms by Site (535) · Hemic and Lymphatic Diseases (309) · Immune System Diseases (228) · Immunoproliferative Disorders (226) · Lymphoproliferative Disorders (222) · Hematologic Diseases (208) · Lymphatic Diseases (187) · Neoplasms, Glandular and Epithelial (184) · Pathological Conditions, Signs and Symptoms (158) · Pathologic Processes (150) · Digestive System Diseases (149) · Digestive System Neoplasms (145) · Skin and Connective Tissue Diseases (145)
Cyclophosphamide (62) · Cisplatin (40) · pembrolizumab (39) · Nivolumab (34) · Radiotherapy (32) · Carboplatin (31) · fludarabine (30) · Dexamethasone (25) · Gemcitabine (25) · Paclitaxel (25) · Bevacizumab (23) · Fluorouracil (22) · fludarabine phosphate (22) · Magnetic Resonance Spectroscopy (20) · Radiosurgery (19)
M.D. Anderson Cancer Center (64) · National Cancer Institute (NCI) (40) · City of Hope Medical Center (16) · Roswell Park Cancer Institute (16) · ImmunityBio, Inc. (12) · Fred Hutchinson Cancer Center (11) · Memorial Sloan Kettering Cancer Center (11) · Bristol-Myers Squibb (10) · Case Comprehensive Cancer Center (10) · Jonsson Comprehensive Cancer Center (10) · University of Alabama at Birmingham (10) · Washington University School of Medicine (10) · Baylor College of Medicine (9) · GlaxoSmithKline (9) · Mayo Clinic (9)
United States (405) · China (41) · Canada (19) · France (15) · Spain (15) · United Kingdom (15) · Germany (14) · Italy (10) · Australia (9) · Belgium (9) · Israel (9) · Netherlands (7) · Singapore (6) · South Korea (6) · Denmark (5)
Lizhi Niu, PhD (5) · David S Schrump, M.D. (4) · Abhishek Maiti, MBBS (2) · Ahmed M Safar, MD (2) · Arnon Nagler, MD (2) · Barbara Gitlitz, MD (2)
PMID 18565579, PMID 18834631, PMID 21123824, PMID 22075702, PMID 24443277, PMID 34515338, PMID 18003886, PMID 18054441, PMID 18390837, PMID 20408846, PMID 22045986, PMID 23586712, PMID 23734882, PMID 23786302, PMID 23815981, PMID 24504486, PMID 24708667, PMID 26187510, PMID 26511652, PMID 27085692, PMID 27112171, PMID 27535748, PMID 27641687, PMID 28805662, PMID 29423221, PMID 31401903, PMID 33203645, PMID 34045232, PMID 35046055, PMID 36402456, PMID 36648215, PMID 37286303, PMID 37741968, PMID 38105538, PMID 38579193, PMID 39863139, PMID 40443562
P30CA033572 (10), P30CA015704 (7), 2016 (4), 2018 (4), 2019 (4), P30CA016056 (4), P30CA016672 (4), P30CA022453 (4), P30CA060553 (4), 2015 (3), P30CA015083 (3), P30CA043703 (3), UM1CA186644 (3), 2014 (2), 2017 (2)